R
The startup is developing a pharmaceutical approach that repurposes approved anti-diabetes medications to treat calcific aortic valve disease, a condition with no current effective treatment. By leveraging the established safety profiles of these drugs, the company aims to slow or halt disease progression in patients with cardiovascular conditions.
Seoul, South Korea
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup is developing a pharmaceutical approach that repurposes approved anti-diabetes medications to treat calcific aortic valve disease, a condition with no current effective treatment. By leveraging the established safety profiles of these drugs, the company aims to slow or halt disease progression in patients with cardiovascular conditions.